December 16, 2011

GENEVA, SWITZERLAND - Global BioDiagnostics Corp. and the Foundation for Innovative New Diagnostics of Geneva, Switzerland announce the extension of their Phase 1 Co-Development Agreement. Click here for more information.

March 1, 2011

GENEVA, SWITZERLAND – Global BioDiagnostics Corp. and the Foundation for Innovative New Diagnostics of Geneva, Switzerland announce the execution of a Phase 1 Co-Development Agreement to develop GBD’s REF based diagnostic technology into a true Point-of-Care TB diagnostic test. Click here for more information.

January 12, 2011

TEMPLE, TEXAS - Global BioDiagnostics Corp. closed a Convertible Unsecured Note financing in the aggregate amount of $185,000. The financing was placed with members of the company's management, management's family, and an existing investor in the company, and will be used to pay for the prosecution of the company's patent portfolio internationally, as well as provide working capital to the company.

October 20, 2010

COLLEGE STATION, TEXAS – Representatives from the Foundation for Innovative New Diagnostics of Geneva, Switzerland meet with GBD’s business and research team to receive briefing on GBD’s REF based diagnostic technology.

July 1, 2010

DARESBURY, UNITED KINGDOM – Global BioDiagnostics Corp. forms wholly owned UK subsidiary, Global BioDiagnostics Limited, and locates its UK based operations on the Daresbury Science and Innovation Campus in Daresbury, United Kingdom. The DSIC is located half-way between Liverpool and Manchester, England. Click here for more information.

June 4, 2010

COLLEGE STATION, TEXAS – Principal Investigator, Dr. Jeffrey D. Cirillo, Texas A&M Health Science Center College of Medicine, with co-authors Dr. James C. Sacchettini and Dr. Jianghong Rao and others, publish “Imaging tuberculosis with endogenous β-lactamase reporter enzyme fluorescence in live mice” in the prestigious journal The Proceedings of the National Academy of Science. Click here for more information.

May 27, 2010

DOHA, QATAR – Global BioDiagnostics Corp.’s REF based diagnostic technology wins one of two Technology Innovation and Entrepreneurship Program awards given by the Qatar Science and Technology Park in collaboration with Carnegie Melon University.
Click here for more information.